International Stem Cell Corporation filings document governance, capital structure and material-event disclosures for a clinical-stage biotechnology issuer. Proxy materials cover annual meeting matters, director elections, executive compensation and equity-award information, including voting mechanics involving preferred stock.
Form 8-K reports record stockholder voting results and material definitive agreements, including related-party debt arrangements with a senior executive. The filings also identify the company's registered-security status under Section 12(b) and provide formal disclosures tied to its public-company governance and financing structure.
International Stem Cell Corporation reported product sales of $2.3 million for the quarter ended March 31, 2026, up from $2.1 million a year earlier, driven mainly by its biomedical segment and modest growth in skin care products. Cost of sales fell, lifting gross margin to 59% from 53%, while operating expenses increased, particularly legal and consulting fees. The company posted a net loss of $0.2 million and ended the quarter with $0.9 million in cash and a related-party note payable of $2.35 million. Management states there is substantial doubt about the company’s ability to continue as a going concern without new financing or extensions of existing debt.
International Stem Cell Corporation is asking stockholders to vote at a virtual annual meeting on June 11, 2026, primarily to elect four directors for one-year terms, including two chosen by holders of Series D Preferred Stock. Stockholders of record as of April 24, 2026 can attend and vote online after pre‑registering.
The company has 8,004,389 common shares outstanding plus several preferred series that vote with common stock, creating significant layered voting power. As of that date, preferred stock was convertible into 7,518,830 common shares, and entities controlled by CEO Andrey Semechkin and EVP/CSO Russell Kern together controlled about 72.3% of preferred voting power. Two independent directors, Paul Maier and Donald Wright, chair the audit and compensation/governance committees. In 2025, the CEO received $88,544 in total compensation and Kern received $370,000, with additional value from outstanding stock options.
The proxy also discloses a related‑party unsecured note: a $2.7 million loan from Semechkin was partially repaid and refinanced, leaving a $2.5 million balance at 5.5% interest, maturing September 25, 2026. Audit fees paid to BDO USA, P.C. were $416,200 in 2025, up from $388,500 in 2024. Stockholders may submit future director nominations and proposals within specified deadlines for the 2027 meeting.
International Stem Cell Corporation is a clinical-stage biotechnology company developing therapies based on human parthenogenetic stem cells, alongside two small revenue-generating units in anti-aging skin care and research cell products. It generated $9.1 million of revenue in both 2025 and 2024 from these commercial businesses, but none yet from its core therapeutic programs.
The company’s lead program uses hpSC-derived neural stem cells (ISC-hpNSC®) for Parkinson’s disease, where a Phase 1 dose-escalation trial has been completed with encouraging safety and preliminary efficacy signals. Additional preclinical work targets traumatic brain injury and stroke. ISCO holds 36 patents and operates cGMP manufacturing in Maryland plus R&D in California.
Management highlights substantial risks: the business remains at an early stage, has a long history of operating losses, and its auditors have expressed substantial doubt about its ability to continue as a going concern. ISCO states it will need significant additional capital to fund ongoing operations and further clinical development, and faces intense competition, complex global regulation, and evolving ethical and legal frameworks around stem cell technologies.
International Stem Cell Corporation reported the results of its annual stockholder meeting held on June 17, 2025. Stockholders elected four directors to serve until the 2026 annual meeting, including Andrey Semechkin and Russell Kern, each receiving 2,457,143 votes for with no votes withheld, and Donald A. Wright and Paul V. Maier, each receiving 7,772,429 votes for and 19,267 votes withheld. Stockholders also approved, on an advisory basis, the compensation of the company’s named executive officers, with 7,715,844 votes for, 73,393 against, and 2,459 abstentions. In addition, stockholders advised that future votes on executive compensation should be held every three years, with 7,593,833 votes favoring a three-year frequency, compared with 142,581 for one year and 50,443 for two years.
International Stem Cell Corporation reported Q3 2025 results. Product sales were $2.369 million, up from $2.179 million a year ago, and income from operations was $94 thousand versus a prior loss. Net income was $57 thousand compared with a net loss of $125 thousand in Q3 2024.
Cash was $966 thousand at quarter-end, and management disclosed “substantial doubt” about the company’s ability to continue as a going concern without additional financing or extensions of existing financing. A related party note payable is presented at $3.305 million within current liabilities, and its maturity was extended to September 15, 2026.
Sales were led by the biomedical segment (LCT) with $2.204 million; the skin care segment (LSC) contributed $165 thousand. One customer accounted for 54% of consolidated product sales in the quarter and 62% of accounts receivable as of September 30, 2025. Basic and diluted EPS were $0.00, with 8,004,389 weighted-average shares.
International Stem Cell Corporation reported that it has amended a loan agreement with its Co-Chairman and Chief Executive Officer, Dr. Andrey Semechkin. The company and Dr. Semechkin agreed to extend the maturity date of a $2,500,000 loan, originally documented in a promissory note dated September 15, 2024, so that the loan is now due on September 15, 2026 instead of the prior 2025 maturity.
The outstanding principal under the note continues to accrue interest at an annual rate of 5.5%, and the company may prepay the note at any time without penalty. The amended note was issued on September 15, 2025, and a form of the note is included as Exhibit 10.1, providing the detailed terms of this insider financing arrangement.
International Stem Cell Corporation reported that it has amended a loan agreement with its Co-Chairman and Chief Executive Officer, Dr. Andrey Semechkin. The company and Dr. Semechkin agreed to extend the maturity date of a $2,500,000 loan, originally documented in a promissory note dated September 15, 2024, so that the loan is now due on September 15, 2026 instead of the prior 2025 maturity.
The outstanding principal under the note continues to accrue interest at an annual rate of 5.5%, and the company may prepay the note at any time without penalty. The amended note was issued on September 15, 2025, and a form of the note is included as Exhibit 10.1, providing the detailed terms of this insider financing arrangement.